Enlight-LN Registry: baseline demographics and clinical characteristics of an initial cohort of patients treated with voclosporin for lupus nephritis in the United States (UKKW 2025) - Jun 9, 2025 - Abstract #456; "In the AURORA 1 and AURORA 2 studies, adding voclosporin to mycophenolate mofetil (MMF) and low-dose glucocorticoids led to significantly earlier and greater reductions in proteinuria while maintaining stable estimated glomerular filtration rate (eGFR) for up to 3 years...A total of 107 patients were on concomitant immunosuppression at voclosporin initiation (most commonly, antimalarials, 72.4%; MMF/mycophenolate sodium, 70.7%; belimumab, 13%)... Baseline data on this initial cohort of patients are reflective of the larger LN population in the US, including high percentages of Black and Hispanic and/or Latino patients. Enrollment of additional patients and ongoing data collection will provide valuable insight into the real-world utilization of voclosporin."
Clinical • Glomerulonephritis • Immunology • Infectious Disease • Inflammatory Arthritis • Lupus • Lupus Nephritis • Nephrology • Renal Disease
|
|
Dr Niloofar Nobakht1; Dr Laura B Geraldino-Pardilla2; Dr Leanna M Wise3; Dr Mohammed Kamgar1; Dr Lily Cipolla4; Dr Lucy Hodge4; Dr Keely Dahl4
|